Kindred Biosciences, Inc. KIN
9.25 0.00 (+0.00%)
Apr 24, 2025, 3:47 PM EDT
9.24 Day range 9.26
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 9.50 +2.7% upside
Now 9.25
- Target (low)
- 9.00
- Target (mean)
- 9.50
- Target (high)
- 11.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 7
- 2 months ago 7
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.16 | -0.28 – 0.01 | 0.60 | -126.7% | 5.40M | -86.4% | 8 |
| Next quarter | -0.19 | -0.26 – -0.08 | -0.31 | +38.7% | 4.67M | +347.7% | 8 |
| Current year | -0.70 | -0.93 – -0.34 | -0.55 | -27.3% | 21.08M | -50.0% | 8 |
| Next year | -0.07 | -0.81 – 1.22 | -0.70 | +90.0% | 53.29M | +152.8% | 8 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 17, 2021 | Lake Street | Downgrade | Buy | Hold |
| Jun 17, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jun 16, 2021 | Aegis Capital | Downgrade | Buy | Hold |
| Jan 26, 2021 | Aegis Capital | Maintained | — | Buy |
| Jul 29, 2020 | Cantor Fitzgerald | Maintained | — | Overweight |
| Mar 17, 2020 | Stifel | Maintained | — | Buy |
| Mar 17, 2020 | H.C. Wainwright | Maintained | — | Buy |
| Jul 16, 2019 | B. Riley | Downgrade | Buy | Neutral |
| Jun 11, 2019 | Barclays | Initiated | — | Overweight |
| May 23, 2019 | Stifel Nicolaus | Initiated | — | Buy |
| Oct 31, 2018 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 7, 2018 | B. Riley FBR | Maintained | Buy | Buy |
| Aug 7, 2018 | Ladenburg Thalmann | Downgrade | Buy | Neutral |
| Jul 24, 2018 | Cantor Fitzgerald | Initiated | — | Overweight |
| Jul 23, 2018 | Lake Street | Initiated | — | Buy |
| Nov 17, 2017 | H.C. Wainwright | Initiated | — | Buy |
| Jun 16, 2017 | Aegis Capital | Initiated | — | Buy |
| May 24, 2017 | FBR Capital | Initiated | — | Outperform |
| Nov 18, 2016 | KeyBanc | Downgrade | Overweight | Sector Weight |
| Nov 1, 2016 | Ladenburg Thalmann | Initiated | — | Buy |
| Nov 17, 2015 | BMO Capital | Downgrade | Outperform | Market Perform |
| Dec 3, 2014 | Leerink Swann | Downgrade | Outperform | Market Perform |
| Apr 14, 2014 | Leerink Swann | Initiated | — | Outperform |
| Mar 7, 2014 | Roth Capital | Downgrade | Buy | Neutral |
| Feb 25, 2014 | BMO Capital | Upgrade | — | Outperform |
| Feb 4, 2014 | Roth Capital | Initiated | — | Buy |
| Jan 22, 2014 | BMO Capital | Downgrade | Outperform | Market Perform |
| Jan 6, 2014 | BMO Capital | Initiated | — | Outperform |